Jamie Goddard

Thought Leader Liaison Lead @ Regeneron | Love my family, food, snow sports and all things tech | Tweet about Healthcare, Technology and Leadership!

[Jamie Goddard @jfgoddard]

@PhilaUnion HERE WE GO!!!

[Jamie Goddard @jfgoddard]

@PhilaUnion @primepoint You gotta hustle Rafanello. You could have helped block DePaul’s goal.

[Jamie Goddard @jfgoddard]

@PhilaUnion @primepoint You have to go to the ball Alladoh

[Jamie Goddard @jfgoddard]

@JoserNunez91 We should have just paid for Tai who we knew could score.

[Regeneron @Regeneron]

#BREAKING: The U.S. FDA has approved our medicine for the treatment of allergic fungal rhinosinusitis (AFRS) in certain people aged 6 years or older. Read more: https://t.co/5tz1YUFHFD

CC: @sanofi

[Professor Claire Hopkins @SnotSurgeon]

Given the news from NICE recommending funding for Dupilumab
- it’s not too late for UK specialists to sign up to try EUFOREA biologics course and learn more about their use in severe CRSwNP
#Euforea

[Jamie Goddard @jfgoddard]

@mamboitaliano__ That’s not Naples

[Jamie Goddard @jfgoddard]

@Regeneron @sanofi H

[Jamie Goddard @jfgoddard]

@QuinnSullivan33 @PhilaUnion Hey Quinn! You’re in good hands with Brian Sennet, MD!! Get well soon!!

[Jamie Goddard @jfgoddard]

@MLS @AppleTV @LigaBBVAMX Don’t say watch at 9pm if the game isn’t starting until 9:45. Bad enough if it started at 9pm. It’s a Wednesday guys. Come on.

[Regeneron @Regeneron]

The FDA granted accelerated approval for our medicine to treat relapsed/refractory #multiplemyeloma after at least four prior lines of therapy. This milestone reflects our relentless commitment to make a meaningful impact in the lives of people living with multiple myeloma.

[Jamie Goddard @jfgoddard]

@NoContextHumans Thants stupid and not real

[Regeneron @Regeneron]

#Breaking: The U.S. FDA approved our medicine for #BullousPemphigoid (BP). Learn what this approval means for adults living with BP, a chronic skin disease. 

CC: @Sanofi

[Regeneron @Regeneron]

Today, we shared interim results from our ongoing Phase 2 trial investigating the ability of our investigational treatments to improve the quality of weight loss when added to GLP-1 treatment. Read more here. https://t.co/R18z10j48v

[Regeneron @Regeneron]

Announcing an in-licensing agreement for an investigational, novel dual GLP-1/GIP receptor agonist that will enable synergy and flexibility across our broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long-term healthAnnouncing an in-licensing agreement for an investigational, novel dual GLP-1/GIP receptor agonist that will enable synergy and flexibility across our broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long-term healthAnnouncing an in-licensing agreement for an investigational, novel dual GLP-1/GIP receptor agonist that will enable synergy and flexibility across our broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long-term health.

[Jamie Goddard @jfgoddard]

@PhilaUnion Beautiful!! Swipe up on photo setting on iPhone to change to 16:9 aspect ratio to get a broader view.

[Regeneron @Regeneron]

Exciting news! Our medicine for #ChronicSpontaneousUrticaria (CSU) is now FDA-approved. This helps fulfill an unmet need for the more than 300,000 eligible people living with this condition in the U.S.

CC: @Sanofi

[Jamie Goddard @jfgoddard]

@PhilaUnion #DOOP DOOP DOOP

[Philadelphia Union @PhilaUnion]

This is an absolute soccer masterpiece. What a ball from Quinn, what a finish by Dani!

Watch on #MLSSeasonPass: https://t.co/vGzcYN4NyP

#DOOP | 🐍 2-1 🦁 (now 3-1 😏)

[Jamie Goddard @jfgoddard]

@PhilaUnion #MLSSeasonPass #doop

[Jamie Goddard @jfgoddard]

@PhilaUnion HERE WE GO UNION!!